We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs.
At Emergent, our mission is to protect and save lives.
GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025.
Emergent BioSolutions will present an overview of historical safety data for ACAM2000® on Thursday, April 24, 2025, at World Vaccine Congress in Washington, D.C. The presentation will be held at 10:10 am eastern time at the Walter E. Washington Convention Center in room 202B and is available to all World Vaccine Congress conference pass holders.
GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock on or before March 27, 2026.
This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.
